Blog

Plus500 (LSE:PLUS) reported an 11% increase in third-quarter revenue to $203.2 million, compared with $182.7 million a year earlier, as customer numbers increased and trading income contributed to revenue growth.

The multi-asset financial technology group recorded quarterly EBITDA of $88.4 million, up 7% from $82.7 million in the corresponding period of 2025, representing an EBITDA margin of 44%.

For the nine months ended 30 September 2026, revenue increased 11% to $666.1 million, while EBITDA rose 3% to $275.9 million.

Following the results, Plus500 said it expects full-year 2026 revenue and EBITDA to exceed current market expectations.

The company also reported progress in expanding its operations in the United States and Latin America, including proposed acquisitions in the US and Brazil and plans to launch a multi-asset trading application in the first quarter of 2027.

Third-Quarter EBITDA Increases 7% to $88.4 Million

Plus500 generated revenue of $203.2 million in the third quarter of 2026, an increase of 11% from $182.7 million in Q3 2025.

EBITDA rose to $88.4 million from $82.7 million, representing year-on-year growth of 7%.

The quarterly EBITDA margin was 44%, reflecting the relationship between revenue growth and operating expenditure during the period.

For the first nine months of 2026, revenue reached $666.1 million, compared with $597.8 million in the corresponding period of 2025.

Trading income increased to $634.0 million from $547.1 million, offsetting a decline in interest income to $32.1 million from $50.7 million.

The company attributed the reduction in interest income to lower global interest rates.

Nine-month EBITDA increased to $275.9 million from $267.8 million, with the company continuing to invest in marketing technology and expanding its operations.

Customer Income, a measure used by Plus500 to assess revenue generated from customer activity, increased 19% to $641.1 million during the first nine months, compared with $536.7 million a year earlier.

Third-quarter Customer Income rose 9% to $180.3 million.

Customer Trading Performance was negative $7.1 million for the nine-month period, compared with positive $10.4 million in the prior year. In the third quarter, the measure was positive $11.9 million, compared with negative $3.6 million a year earlier.

Plus500 maintained its expectation that Customer Trading Performance will remain broadly neutral over time.

New Customer Numbers Increase 27% as Acquisition Costs Decline

Plus500 reported 28,747 new customers during the third quarter, an increase of 27% from 22,644 in Q3 2025.

The number of active customers increased 4% to 119,528, compared with 115,327 in the previous year.

Average revenue per user rose 7% to $1,700 from $1,584, while average user acquisition cost declined 14% to $1,150 from $1,344.

For the first nine months of 2026, new customer numbers increased 20% to 94,470, compared with 78,809 during the corresponding period of 2025.

Active customers increased 10% to 230,287, while average revenue per user rose 2% to $2,893.

Average user acquisition cost for the nine-month period declined 5% to $1,206.

Customer deposits totalled $1.9 billion during the third quarter, compared with $1.7 billion a year earlier.

Average deposits per active customer increased approximately 7% to $15,800 from $14,700.

For the first nine months, customer deposits reached $5.3 billion, compared with $4.8 billion in 2025.

US Non-OTC Business Accounts for 16% of Nine-Month Revenue

Plus500 reported further expansion of its non-over-the-counter (non-OTC) business, which includes futures, options on futures and prediction market products.

The segment accounted for approximately 16% of group revenue and 31% of new customers during the first nine months of 2026.

Customer segregated funds exceeded $1 billion at 30 September 2026.

The company also announced two business partnerships with Wealthsimple and Nelogica, expanding the distribution of its trading technology and infrastructure through business-to-business and business-to-business-to-consumer channels.

Plus500’s existing institutional relationships also include Topstep.

During the period, the group introduced additional US trading products, including Commodity Futures Trading Commission-regulated sports and non-sports prediction market contracts and single-stock futures.

The company said it intends to introduce further products as it expands its US operations.

Plus500 Plans US Multi-Asset Trading App for First Quarter of 2027

Plus500 outlined plans to launch a new multi-asset trading application in the United States during the first quarter of 2027.

The proposed platform is intended to combine access to futures, options on futures, prediction markets, equities, options and exchange-traded funds within a single application.

The development is linked to Plus500’s recently announced conditional acquisition of Hedge Capital Markets, a US broker-dealer.

The acquisition would provide access to markets regulated by the US Securities and Exchange Commission, complementing Plus500’s existing operations regulated by the Commodity Futures Trading Commission.

The company plans to use its proprietary technology to integrate the additional securities products into its existing trading infrastructure.

Following the proposed US launch, Plus500 intends to consider introducing the application in other international markets.

The company has not disclosed a specific launch date within the first quarter or provided financial projections for the new platform.

Proposed Broker-Dealer Acquisitions Expand Operations in US and Brazil

Alongside its US expansion plans, Plus500 announced the conditional acquisition of Guru, a regulated broker-dealer in Brazil.

The transaction is intended to establish the company’s first locally regulated operations in Brazil and enable it to begin onboarding customers in the country.

Plus500 already has a business partnership with Brazilian financial technology company Nelogica and maintains a presence in Colombia.

The proposed acquisition would extend its direct operations in Latin America and provide access to additional products and customer segments.

Both the Hedge and Guru acquisitions are expected to be funded entirely from Plus500’s existing cash resources.

The company has not disclosed the financial terms of the transactions in its latest trading update.

Plus500 Expands Trading Hours and Product Availability

Plus500 continued developing its OTC trading business during the period, introducing extended trading hours for selected financial instruments.

The company launched 24-hour trading on stocks and exchange-traded funds during five days of the week.

Shortly after the third quarter ended, it expanded trading availability to include 24-hour, seven-day access to gold, silver, oil and natural gas products.

Plus500 also introduced new daily options contracts.

The additions form part of the group’s strategy to expand its product range and provide customers with access to different markets and trading schedules.

Cash Exceeds $775 Million Following Dividends and Share Buybacks

Plus500 reported cash balances exceeding $775 million at 30 September 2026 and confirmed that the group remained debt-free.

During the third quarter, the company paid dividends totalling $87.4 million and repurchased approximately $63.5 million of its shares.

At the end of September, Plus500 held 43,980,450 ordinary shares in treasury, representing approximately 38% of its issued share capital.

Since beginning its share repurchase programmes in 2017, the company has acquired a total of 51,113,187 ordinary shares at an average price of £17.70 per share.

The reported cumulative figure excludes shares subsequently issued from treasury under equity-based compensation arrangements.

Shares held in treasury do not carry voting rights or dividend entitlements.

Plus500 said its capital allocation strategy continues to include investment in existing operations, potential acquisitions and shareholder distributions.

Plus500 Expects Full-Year Revenue and EBITDA to Exceed Market Forecasts

Following its performance during the first nine months of 2026, Plus500’s board expects full-year revenue and EBITDA to exceed current market expectations.

The company did not provide revised numerical guidance in its trading update.

Chief Executive Officer David Zruia attributed the group’s performance to customer acquisition, expansion of its non-OTC activities and the introduction of additional trading products.

Management also identified the proposed acquisitions in the US and Brazil as part of its strategy to enter new regulated markets and broaden its international operations.

Plus500 operates across more than 60 countries and continues to develop its proprietary trading technology for retail and institutional customers.

The company’s remaining 2026 activities include progressing its proposed acquisitions, developing additional trading products and preparing for the planned US multi-asset application launch in early 2027.

Empyrean Energy plc (LSE:EME) has provided an update on its planned investment in the GOLD Cluster gas exploration project in Upper Austria, confirming that construction of the GOLD-1 wellsite is scheduled to begin on 27 October 2026, with drilling expected to commence in the first week of January 2027.

The oil and gas exploration and development company is working towards finalising an Exploration and Investment Agreement (EIA) with ADX VIE GmbH (ADX.V), under which Empyrean would acquire a 10% economic interest in the GOLD Cluster.

Both companies expect to execute the agreement by 30 October 2026, allowing additional time to complete the associated partnership arrangements.

The revised drilling timetable reflects rig availability and operational considerations associated with equipment mobilisation and staffing during the Christmas and New Year period.

Empyrean and ADX Target 30 October Agreement

Empyrean and ADX.V are continuing negotiations to finalise the Exploration and Investment Agreement governing Empyrean’s proposed participation in the GOLD Cluster.

Under the proposed transaction, Empyrean would acquire a 10% economic interest in the exploration project, which is currently held entirely by ADX.V.

The companies expect to sign the EIA by 30 October 2026, following completion of the associated partnership documentation.

The agreement is intended to establish the contractual framework for Empyrean’s participation in the project and the progression of planned exploration activities.

Empyrean initially outlined the proposed investment in an announcement dated 14 September 2026.

The company has not announced completion of the agreement, and its proposed economic interest remains subject to the transaction being finalised.

GOLD Cluster Covers 73 Square Kilometres in Upper Austria

The GOLD Cluster comprises three shallow gas exploration prospects: GOLD, ZAUN and GRAB.

The prospects are located within the Molasse Basin in Upper Austria and cover approximately 73 square kilometres of the ADX-AT-II exploration licence area.

ADX.V currently holds a 100% interest in the licence area containing the prospects.

Empyrean’s proposed 10% economic participation would provide exposure to exploration activities across the GOLD Cluster, subject to the terms of the final agreement.

The GOLD-1 well is the next planned drilling activity within the project.

The company’s latest announcement did not provide updated prospective resource estimates, drilling costs or additional geological information for the three prospects.

GOLD-1 Wellsite Construction Scheduled to Begin on 27 October

Preparations for the GOLD-1 exploration well are progressing, with construction of the wellsite scheduled to commence on 27 October 2026.

The work forms part of the preparations required before drilling operations can begin.

Empyrean confirmed that planning for the drilling programme is underway, with the well expected to be spudded during the first week of January 2027.

The company said the timetable takes account of drilling rig availability and the operational considerations associated with working over the year-end holiday period.

Equipment mobilisation, personnel availability and drilling activities can be affected by the Christmas and New Year period, according to Empyrean.

The January schedule is intended to accommodate these factors while allowing site preparations and partnership arrangements to progress.

No specific drilling completion date or timetable for exploration results was provided.

Empyrean Outlines Next Steps for Austrian Gas Exploration

Empyrean Chief Executive Officer Gaz Bisht said the company is continuing to work with ADX.V to complete the EIA and related partnership agreements.

He explained that the planned January drilling date reflects rig availability and the decision to avoid potential operational inefficiencies associated with mobilisation during the festive period.

Management said its immediate priorities remain finalising the contractual arrangements, progressing wellsite construction and preparing for the GOLD-1 drilling programme.

The company has not disclosed any changes to the proposed 10% economic interest or announced additional financial commitments in its latest update.

Empyrean maintains exploration and development interests in Austria, Indonesia and the United States.

The GOLD Cluster represents part of its Austrian exploration activities, with the next scheduled milestones being execution of the investment agreement, commencement of site construction and the planned drilling of GOLD-1 in January 2027.

Avacta Therapeutics (LSE:AVCT) has reported updated Phase 1a/1b clinical trial results for faridoxorubicin (AVA6000), showing median progression-free survival (PFS) of 11.4 months in a selected group of 32 patients with salivary gland cancer.

The results, presented at the European Society for Medical Oncology (ESMO) Congress in Madrid, compare with published historical median PFS benchmarks of 6 to 6.7 months for earlier-line treatments.

The company also reported three partial tumour responses and six minor responses among the 32 patients included in the efficacy analysis, with response durations ranging from 18.7 to 72 weeks.

Avacta said additional imaging and pharmacokinetic data indicated continued release of the chemotherapy agent doxorubicin within tumours beyond 10 treatment cycles.

The findings are from an ongoing early-stage clinical trial, and the comparison with historical treatment outcomes is not based on a randomised control group.

AVA6000 Records Median Progression-Free Survival of 11.4 Months

Avacta’s latest analysis included 32 patients with salivary gland cancer who received faridoxorubicin at doses of at least 310 mg/m².

The group was selected from 51 patients with salivary gland cancer enrolled across the Phase 1a/1b trial, with certain rare cancer subtypes and patients who had received more extensive prior treatment excluded from the reported efficacy analysis.

At the data cutoff of 5 October 2026, median progression-free survival in the selected population was 11.4 months, with a 95% confidence interval ranging from seven months to an upper limit that had not been reached.

The company compared this result with historical median PFS figures of 6 to 6.7 months reported in published studies of chemotherapy and targeted treatments used in first- and second-line settings.

These historical comparisons provide context but do not establish that AVA6000 is more effective than existing treatments, as the trial did not directly compare patients receiving faridoxorubicin with a concurrent control group.

Median overall survival had not been reached at the October data cutoff.

Avacta described the treatment as well tolerated within the reported patient subset, although the announcement did not provide detailed adverse-event rates.

Nine Patients Show Partial or Minor Tumour Responses

Within the 32-patient efficacy population, Avacta reported three partial responses and six minor responses.

The observed responses lasted between 18.7 and 72 weeks.

The company said the results provide evidence of antitumour activity in patients with salivary gland cancers, a group of malignancies included in the trial because of their potential expression of fibroblast activation protein (FAP).

Faridoxorubicin is designed to deliver doxorubicin, an established chemotherapy agent, through Avacta’s pre|CISION peptide-drug conjugate technology.

The treatment is intended to release doxorubicin in the tumour microenvironment through the activity of FAP, an enzyme associated with certain tumour tissues.

The ongoing trial is assessing safety, pharmacokinetics and preliminary efficacy in patients with FAP-positive solid tumours.

AVA6000 is administered by intravenous infusion either every two weeks or every three weeks, depending on the treatment schedule.

In addition to salivary gland cancer, the Phase 1b expansion includes patients with soft tissue sarcoma and triple-negative breast cancer.

Avacta said data from the latter two cancer groups are continuing to mature.

Imaging Data Indicate Continued FAP Activity During Treatment

Avacta also presented findings from FAP inhibitor positron emission tomography (FAPI-PET) imaging and pharmacokinetic studies examining the activity of faridoxorubicin over repeated treatment cycles.

According to the company, imaging and tumour tissue analysis indicated that FAP expression was maintained over time in multiple tumour types, including in patients experiencing tumour responses.

Plasma pharmacokinetic measurements extending to 12 treatment cycles showed continued cleavage of faridoxorubicin into its peptide component and doxorubicin.

Avacta said these findings indicate that FAP-mediated drug release can persist during prolonged treatment.

Tumour biopsy data also showed a reported 100:1 concentration ratio of released doxorubicin in tumour tissue relative to plasma.

The company reported tumour reductions in patients whose samples showed relatively low FAP expression, classified as 1+.

These observations form part of Avacta’s investigation into whether its drug delivery platform can maintain chemotherapy exposure within tumours over multiple treatment cycles.

Preclinical Findings Support Further Investigation of Drug Release Mechanism

Alongside the clinical findings, Avacta referred to preclinical data from its next-generation drug candidate, FAP-Exd (AVA6103), which were also presented at ESMO.

The preclinical research suggests that treatment may lead to the recruitment of additional FAP-positive fibroblasts into tumour tissue.

Avacta believes this process could contribute to sustained drug activation as treatment continues, including when tumours decrease in size.

The company said the findings may help explain the continued release of doxorubicin observed in the AVA6000 clinical trial.

However, the proposed mechanism is supported by preclinical research and requires further evaluation to establish its clinical relevance.

AVA6103 is a next-generation pre|CISION peptide-drug conjugate designed to use FAP-mediated activation to release its therapeutic payload.

Avacta expects to present additional tumour pharmacokinetic and drug-release data for AVA6103 in late 2026, followed by initial efficacy data during the first half of 2027.

Avacta and Clinical Investigators Comment on ESMO Findings

Christina Coughlin, Chief Executive Officer of Avacta, said the updated clinical and preclinical datasets support the company’s research into sustained delivery of chemotherapy agents within tumour tissue.

Management believes the findings provide evidence that the pre|CISION platform can maintain drug activation over prolonged treatment periods.

The company also considers the data relevant to its development of AVA6103, which is intended to build on the drug delivery approach used in faridoxorubicin.

Alan Ho, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center in New York and senior author of the ESMO presentation, highlighted the disease-control observations in patients with salivary gland cancers.

He also identified the FAPI-PET imaging findings as relevant to understanding FAP expression during treatment.

The company has not announced a change to the clinical development programme for AVA6000 or provided a timetable for any potential regulatory submission.

Further Clinical Data Expected From Avacta’s Oncology Pipeline

Avacta is continuing its Phase 1a/1b evaluation of faridoxorubicin, with additional data from patients with soft tissue sarcoma and triple-negative breast cancer still being collected.

The company is also progressing AVA6103 as part of its next-generation pre|CISION development programme.

Its planned milestones include further pharmacokinetic and drug-release findings for AVA6103 before the end of 2026 and initial efficacy results in the first half of 2027.

The latest AVA6000 findings provide preliminary clinical evidence of antitumour activity and progression-free survival outcomes in a selected salivary gland cancer population.

Further clinical investigation will be needed to establish the treatment’s efficacy, safety profile and comparative performance against existing therapies.

Georgina Energy Plc (LSE:GEX) has provided an operational update on its Hussar EP513 helium, hydrogen and natural gas exploration project in Western Australia, confirming that preparations at the drilling site are complete while weather-related road restrictions continue to delay the mobilisation of the Ensign 970 drilling rig.

The company is working with Ensign Energy Services to develop a revised mobilisation plan, including the assessment of alternative access routes to the Hussar 2 wellsite.

Georgina said all civil engineering and site preparation activities required for drilling have been completed, with contractors and their equipment having demobilised from the location.

The company intends to announce a revised drilling commencement date once access arrangements have been finalised.

Road Closures and Weather Conditions Affect Hussar Drilling Schedule

Georgina reported that continuing restrictions on heavy vehicle movements and variable weather conditions have prevented the Ensign 970 drilling rig from reaching the Hussar site.

The company and its operating partner, Westmarket Oil & Gas Pty Ltd (WMOG), are assessing alternative transport arrangements to facilitate mobilisation.

Georgina stated that neither it nor WMOG has received notification of any requirement to pay AU$10 million in road access costs. It also said neither party had been notified of such a payment being necessary before using council-administered roads.

According to the company, WMOG and its contractors are currently using these roads for operational activities.

WMOG has undertaken road improvement work at its own expense along the Eagle Highway, from the Mangkili turnoff on the Gunbarrel Highway to the proposed Hussar 2 site.

The company said the work also included upgrading the local wellsite airstrip to the required specifications, with plans to install emergency runway lighting.

Georgina has engaged consulting engineers Aztech and Ingenua to examine access options for the Ensign 970 rig.

Ingenua is reviewing a proposed Road User Agreement and is in discussions with stakeholders, including the Shire of Wiluna, the Western Australian Main Roads Department and the Shire of Leonora.

One alternative route under consideration would approach the site via Leonora, following the Great Central Road and David Carnegie Highway before connecting to the Eagle Highway.

Georgina said it is prioritising personnel and equipment safety while working towards resolving the access restrictions.

Seismic Survey Planned Subject to Regulatory and Heritage Approvals

Alongside preparations for drilling, Georgina is progressing a seismic exploration programme at Hussar that remains subject to final approvals.

The company expects the survey to require approximately 30 days of fieldwork once the necessary authorisations have been obtained.

Unlike the drilling rig mobilisation, the planned seismic activities will not require heavy vehicle access.

Georgina intends to use lightweight seismic equipment, including vibration sources mounted on rubber-tyred or crawler vehicles.

The proposed technology is designed to operate without clearing or grading seismic lines and without deploying extended geophone cables.

The survey will also incorporate wireless data collection systems using Bluetooth Low Energy or other wireless transmission technology.

The programme remains subject to approvals from the relevant Western Australian mining and petroleum authorities and Traditional Owner cultural heritage processes.

Georgina said it expects the outstanding approvals shortly, although no confirmed commencement date has been provided.

Hussar Well Targets Helium, Hydrogen and Natural Gas at Approximately 3,200 Metres

The Hussar prospect is located within Exploration Permit EP513 in the Officer Basin of Western Australia.

The proposed exploration well is designed to investigate subsalt reservoir formations, including the Townsend Formation and fractured Neoproterozoic basement rocks.

These formations represent the primary exploration targets for helium, hydrogen and natural gas.

Georgina plans to drill to an initial total depth of approximately 3,200 metres, with the possibility of extending the well depending on encountered gas indications and reservoir characteristics.

The company has also identified secondary hydrocarbon gas targets within the overlying Kanpa and Hussar formations.

According to Georgina, previous drilling has identified hydrocarbon indications and reservoir porosity within these formations, although they have not been adequately tested.

The proposed Hussar well is intended to provide further geological and reservoir information to assess the prospect’s resource potential.

Independent Report Estimates Prospective Resources of 283 BCF Helium and 315 BCF Hydrogen

Georgina referenced an independent geological report dated 1 February 2026, prepared by Competent Person Maki Petkovski, which assessed the prospective resources associated with the Hussar project.

The report identified unrisked, net attributable 2U prospective resources of 283 billion cubic feet (BCF) of helium, 315 BCF of hydrogen and 2.93 trillion cubic feet (TCF) of hydrocarbon gas.

These figures are prospective resource estimates rather than confirmed reserves or commercially recoverable quantities.

The company also presented an estimated combined unrisked in-situ value of approximately US$152 billion, based on assumed prices of US$450 per thousand cubic feet of helium, US$2.65 per kilogram of hydrogen and US$8 per thousand cubic feet of hydrocarbon gas.

Georgina said the valuation was developed using pricing references from the Australian Energy Regulator and the Helium Price Index.

The estimated figure represents a theoretical in-situ resource value and does not constitute a project valuation, revenue forecast or estimate of future profit.

It excludes production, gas separation and transportation costs, and the company acknowledged that there is no certainty any portion of the prospective resources will be commercially recovered.

Further exploration, drilling and technical evaluation will be required to establish the presence, extent and commercial viability of any discovered resources.

Georgina Energy Maintains Hussar Development Plans

Georgina said its immediate operational focus remains on securing suitable access for the Ensign 970 drilling rig and establishing a revised commencement date for the Hussar exploration well.

Chief Executive Officer Anthony Hamilton said the company expects to address the weather-related road restrictions through further planning and continues to prioritise drilling the Hussar prospect for its helium and hydrogen potential.

The company has not provided a revised drilling timetable or quantified the financial impact of the mobilisation delays.

Georgina intends to issue further updates as access arrangements progress, including additional site photographs and details of the revised drilling schedule.

The company continues to pursue its exploration and development activities at Hussar, with drilling and seismic work intended to provide further information on the project’s subsurface resources.

Computacenter plc (LSE:CCC) has raised its full-year 2026 adjusted profit before tax outlook to at least £425 million following third-quarter trading that exceeded management’s expectations, supported by growth in Technology Sourcing and Professional Services.

The technology and services provider reported increased demand from hyperscale and neocloud customers in North America and the UK during the three months ended 30 September 2026.

Group Technology Sourcing revenue increased compared with the previous year, while Services revenue also grew, as higher Professional Services revenue more than offset a decline in Managed Services.

Computacenter ended September with a committed product order backlog of £12.6 billion, up from £9.3 billion at the end of June, representing an increase of £3.3 billion, or approximately 35.5%.

The company said its revised profit expectations reflect third-quarter performance and trading during the opening weeks of the fourth quarter.

North America Drives Growth in Technology Sourcing and Professional Services

Computacenter reported continued growth across its North American operations, supported by project completions and demand from hyperscale and neocloud customers.

The region recorded its highest level of project completions during the quarter, contributing to revenue growth in both Technology Sourcing and Professional Services.

North America also reported an increase in its committed product order backlog, reflecting additional customer orders.

The company identified the region as a principal contributor to its third-quarter performance, alongside continued demand from UK customers.

Group Technology Sourcing revenue benefited from customer activity in both markets, while Professional Services recorded organic growth, primarily driven by North America.

Managed Services revenue declined compared with the corresponding period last year, although growth in Professional Services was sufficient to deliver an overall increase in Group Services revenue.

Computacenter did not provide individual divisional revenue figures or regional growth percentages in its third-quarter update.

UK Technology Sourcing Revenue Increases as Germany Maintains Underlying Performance

Computacenter reported growth in its UK operations during the September quarter, with Technology Sourcing recording an increase in revenue.

Professional Services revenue also rose in the UK, contributing to the group’s overall Services performance.

In Germany, Technology Sourcing revenue increased compared with the prior-year period, while Professional Services revenue remained broadly stable.

The company said it continues to implement measures intended to improve operational efficiency and align resources with customer demand in Germany.

These actions were previously outlined in Computacenter’s half-year results.

The trading update did not provide additional financial details regarding the German efficiency programme or specify any associated costs or savings.

Committed Product Order Backlog Reaches £12.6 Billion

Computacenter reported a committed product order backlog of £12.6 billion at the end of September 2026, compared with £9.3 billion three months earlier.

The £3.3 billion quarterly increase reflects growth in committed customer orders, with North America contributing to the expansion.

The company also reported an ongoing pipeline of business opportunities in North America and the UK.

Computacenter said the backlog and current trading conditions were factors supporting its updated financial outlook.

The company did not provide a timetable for converting the full order backlog into revenue.

Computacenter Expects Adjusted Profit Before Tax of at Least £425 Million

Following the third-quarter performance and the start of fourth-quarter trading, Computacenter now expects adjusted profit before tax for FY2026 to be no less than £425 million.

The revised guidance follows the company’s first-half performance and continued growth in Technology Sourcing and Professional Services during the September quarter.

Computacenter said the increase in its full-year expectations reflects trading ahead of its previous assumptions.

The company did not disclose a revised full-year revenue forecast or provide additional guidance for individual business divisions.

The third-quarter trading information remains unaudited.

Capital Markets Event Scheduled for 24 November

Computacenter will host a Capital Markets Event on 24 November 2026 at its Hatfield facilities in Hertfordshire.

The event will be led by Chief Executive Officer Mike Norris and Chief Financial Officer Keith Mortimer, alongside presentations from senior management.

Topics will include the company’s growth opportunities in North America and its European data centre capabilities.

Attendees will also be offered a visit to Computacenter’s Hatfield Integration Center and its new Liquid Cooling Facility.

The company is scheduled to publish its next trading update on 28 January 2027, when it will provide a pre-close assessment of its full-year performance.